TheStreet's Jim Cramer says investors shouldn't be making stock trades based on who President-elect Donald Trump is nominating to his Cabinet. Trump has selected Rep. Tom Price, R-Ga., and an Obamacare critic to head the Department of Health and Human Services. Cramer says investors shouldn't be buying stocks such as Stryker (SYK) and Zimmer Biomet (ZBH) based on the nomination, noting that companies reported weak quarters. "This is a little bit nuts when you see a bunch of stocks go up on an appointment," says Cramer. He said investors should ring the register because he doesn't want people to get hurt.
More from Video
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.